Fumonisin B2-13C34 (FB2-13C34) is intended for use as an internal standard for the quantification of FB2 (Item No. 13227) by GC- or LC-MS. FB2 is a mycotoxin that has been found in F. moniliforme.{1632} It is cytotoxic against a panel of seven rat hepatoma cell lines (IC50s = 3-50 µg/ml), as well as MDCK cells (IC50 = 2 µg/ml).{59489} FB2 (125-1,000 µM) is also cytotoxic to primary rat hepatocytes and induces hepatocyte nodule formation, a marker of cancer initiation, in rats when administered at a dose of 1,000 mg/kg for 21 days.{61109} FB2 has been detected in corn and corn-based foods and livestock feeds.{61110}
Available on backorder
An internal standard for the quantification of fumonisin B2 by GC- or LC-MS
Formal name: (2R,2’R)-2,2′-((((5R,6R,7S,9S,16R,18S,19S)-19-amino-16,18-dihydroxy-5,9-di(methyl-13C)icosane-6,7-diyl-1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20-13C20)bis(oxy))bis(2-oxoethane-2,1-diyl-1,2-13C2))disuccinic-13C4 acid
Synonyms: FB2
Molecular weight: 739.6
CAS: 1217481-36-1
Purity: ≥98%
Formulation: A 1:1 solution in acetonitrile:water
The nuclear factor-κB (NF-κB) regulates the expression of numerous genes involved in immunity and inflammation, cellular stress responses, growth, and apoptosis. Resveratrol, a polyphenolic trans-stilbene, is a known inhibitor of the activation of NF-κB and exhibits activity against a wide variety of cancer cells. CAY10512 is a substituted trans-stilbene analog of resveratrol that is 100-fold more potent as measured by antioxidant activity. The IC50 value for inhibition of TNFα-induced activation of NF-κB by CAY10512 is 0.15 µM compared to 20 µM by resveratrol.{14545}
Available on backorder
1,2-Dipalmitoyl-sn-glycero-3-PC (DPPC) is a zwitterionic glycerophospholipid commonly used in the formation of lipid monolayers, bilayers, and liposomes for use in a variety of applications.{14480,24261,14478,14479} It has been used in the formation of proteoliposomes for implantation of γ-glutamyl transpeptidase into human erythrocyte membranes.{14478} Incorporation of glycosphingolipid antigens into DPPC-containing liposomes increases the immunogenicity of the antigens in mice.{14479}
Available on backorder
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}
Available on backorder
The tetracycline repressor (TetR) is a transcriptional regulator which normally binds tightly to its palindromic tetO operator DNA, blocking gene expression.{17508} Tet causes the repressor to dissociate from the DNA, allowing transcription to occur. A novel reverse TetR (revTetR) requires tetracycline as a co-repressor to bind tetO and block transcription.{17509,17510} Anhydrotetracycline (hydrochloride) is a powerful effector in both the tetracycline repressor (TetR) and reverse TetR (revTetR) systems, binding the Tet repressor 35-fold more strongly than Tet.{17508,17511} Moreover, anhydrotetracycline poorly binds the 30S ribosomal subunit, compared to Tet,{17512} so it does not act as a general inhibitor of translation and is a poor antibiotic. Perhaps related to this, the concentration of anhydrotetracycline that inhibits eukaryotic cell growth is more than a 1,000-fold above the dose that alters transcription through TetR.{17508}
Available on backorder